OKYO Pharma: Chairman's Entity Buys 50,000 Shares
Ticker: OKYO · Form: 6-K · Filed: Sep 10, 2024 · CIK: 1849296
Sentiment: neutral
Topics: insider-buy, share-purchase, company-update
TL;DR
OKYO Pharma chairman's related party bought 50K shares.
AI Summary
On September 10, 2024, OKYO Pharma Ltd announced that Panetta Partners Limited, an entity with a beneficial interest held by Executive Chairman Gabriele Cerrone, purchased 50,000 ordinary shares of the company. The filing does not specify the dollar amount of this transaction.
Why It Matters
This purchase by an entity associated with the Executive Chairman could signal confidence in the company's future prospects.
Risk Assessment
Risk Level: medium — Insider buying can be a positive signal, but the overall impact depends on the company's financial health and market conditions.
Key Numbers
- 50,000 — Ordinary Shares Purchased (Acquired by Panetta Partners Limited, an entity linked to the Executive Chairman.)
Key Players & Entities
- OKYO Pharma LTD (company) — Company making the announcement
- Panetta Partners Limited (company) — Entity that purchased shares
- Gabriele Cerrone (person) — Executive Chairman with beneficial interest in Panetta Partners Limited
- 50,000 (dollar_amount) — Number of ordinary shares purchased
FAQ
What was the date of the announcement regarding the share purchase?
The announcement was made on September 10, 2024.
Who is Gabriele Cerrone?
Gabriele Cerrone is the Executive Chairman of OKYO Pharma LTD and has a beneficial interest in Panetta Partners Limited.
Which entity purchased the shares?
Panetta Partners Limited purchased 50,000 ordinary shares of OKYO Pharma LTD.
How many shares were purchased?
50,000 ordinary shares were purchased.
What type of filing is this?
This is a Form 6-K filing, which is a Report of Foreign Private Issuer.
Filing Stats: 373 words · 1 min read · ~1 pages · Grade level 13.4 · Accepted 2024-09-10 07:00:08
Key Financial Figures
- $1.03 — dinary shares on NASDAQ at a price of US$1.03 per share. This brings the total shareh
Filing Documents
- form6-k.htm (6-K) — 24KB
- ex99-1.htm (EX-99.1) — 10KB
- ex99-1_001.jpg (GRAPHIC) — 9KB
- 0001493152-24-035581.txt ( ) — 47KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. OKYO Pharma LTD Date: September 10, 2024 By: /s/ Keeren Shah Name: Keeren Shah Title: Chief Financial Officer 3 EXHIBIT INDEX Exhibit No. Description 99.1 News Announcement, dated September 10, 2024 4